Stockscreener 앱 받기
0.2658
7.93%
-0.0242
전일 마감가:
$0.29
열려 있는:
$0.2898
하루 거래량:
4.99M
Relative Volume:
0.69
시가총액:
$7.41M
수익:
$9.94M
순이익/손실:
$-144.49M
주가수익비율:
-0.0475
EPS:
-5.5956
순현금흐름:
$-103.90M
1주 성능:
-2.94%
1개월 성능:
-88.08%
6개월 성능:
-95.27%
1년 성능:
-90.79%
1일 변동 폭
$0.26
$0.2898
1주일 범위
$0.183
$0.3735
52주 변동 폭
$0.183
$8.17
Syros Pharmaceuticals Inc Stock (SYRS) Company Profile
명칭
Syros Pharmaceuticals Inc
전화
617-744-1340
주소
35 CAMBRIDGE PARK DRIVE, CAMBRIDGE
SYRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| SYRS | 0.2659 | 7.41M | 9.94M | -144.49M | -103.90M | -5.5956 |
| VRTX | 449.19 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.15 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 599.00 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.91 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.97 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-11-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-22 | 개시 | Alliance Global Partners | Buy |
| 2020-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-03-08 | 재개 | JMP Securities | Mkt Outperform |
| 2019-02-14 | 재개 | Oppenheimer | Outperform |
| 2018-11-05 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2018-03-13 | 재확인 | Wedbush | Outperform |
| 2017-10-31 | 재개 | Piper Jaffray | Overweight |
| 2017-10-23 | 개시 | ROTH Capital | Neutral |
| 2017-08-10 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
모두보기
Syros Pharmaceuticals Inc 주식(SYRS)의 최신 뉴스
Syros pharmaceuticals chief medical officer sells shares for $2,382 By Investing.com - Investing.com Australia
Syros Pharmaceuticals chief legal officer sells $10,320 in stock By Investing.com - Investing.com Australia
Syros pharmaceuticals chief medical officer sells shares for $2,382 - Investing.com India
Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 - Investing.com
Syros pharmaceuticals chief development officer sells shares for $7,949 By Investing.com - Investing.com UK
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call Transcript - MSN
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal - MSN
Brookline Capital Downgrades Syros Pharmaceuticals (SYRS) - MSN
Syros cut to neutral by H.C. Wainwright on failed drug study - MSN
Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes - XM
Syros Pharmaceuticals Faces Financial Struggles Amid Key Challenges - TipRanks
What is HC Wainwright’s Forecast for SYRS Q1 Earnings? - Defense World
Avidity Partners Management LP's Strategic Acquisition in Syros Pharmaceuticals Inc - GuruFocus.com
Blue Owl Capital Holdings LP Increases Stake in Syros Pharmaceuticals Inc - GuruFocus.com
Syros Pharmaceuticals (NASDAQ:SYRS) Earns Neutral Rating from HC Wainwright - Defense World
Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright - Yahoo Finance
JMP Securities cuts Syros Pharma stock rating following unsuccessful trial By Investing.com - Investing.com Australia
Syros Pharmaceuticals' SWOT analysis: stock faces headwinds after trial setback - Investing.com Canada
No RARA, Syros trouble: MDS phase III sinks tamibarotene - BioWorld Online
Syros’s Hopes Dashed As Tamibarotene Flunks Phase III MDS Trial - Citeline News & Insights
Syros Pharmaceuticals stock hits 52-week low at $0.4 By Investing.com - Investing.com Canada
JMP Securities cuts Syros Pharma stock to Market Perform - Investing.com
U.S. Stock market: Syros Pharmaceuticals(−86.21%), GlucoTrack(−77.70%) and others among the most volatile stocks during mid day trading - Business Upturn
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default - Benzinga
Syros Pharmaceuticals downgraded to Hold from Buy at TD Cowen - TipRanks
Syros Pharmaceuticals stock hits 52-week low at $0.4 - Investing.com
Syros stock craters after lead cancer therapy flops in Phase III trial - Pharmaceutical Technology
U.S. Stock market: Syros Pharmaceuticals surges by 680.00% while Spirit Airlines rises by 184.96% in early trading - Business Upturn
Syros flunks phase 3 blood cancer trial, triggering loan default and share-price plunge - Fierce Biotech
Syros Pharmaceuticals' (SYRS) Hold Rating Reiterated at Brookline Capital Management - MarketBeat
Analysts Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Target Price at $5.00 - MarketBeat
JMP Securities Reiterates Market Perform Rating for Syros Pharmaceuticals (NASDAQ:SYRS) - MarketBeat
Syros Pharmaceuticals' (SYRS) "Hold" Rating Reaffirmed at TD Cowen - MarketBeat
Syros Pharmaceuticals Shares Plummet Premarket After Study Failure - MarketWatch
Syros Crashes Over 90% on Late-Stage MDS Fail, Loan Default - BioSpace
TD Cowen downgrades Syros Pharma stock to Hold on trial failure - Investing.com
Syros downgraded to Market Perform from Outperform at JMP Securities - TipRanks
Syros stock dives 92% on failed Phase 3 study, possible loan default (update) - MSN
Syros Pharmaceuticals trial fails to meet primary goal - Investing.com
Syros Pharmaceuticals trial fails to meet primary goal By Investing.com - Investing.com UK
Syros Pharma Stock Alert: Phase 3 Trial Fails, Loan Default Triggered | SYRS Stock News - StockTitan
Syros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Sell at StockNews.com - MarketBeat
SYRS (Syros Pharmaceuticals) Total Inventories : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
Syros Pharmaceuticals, Inc. announced that it expects to receive $10 million in funding from Incyte Corporation - Marketscreener.com
Incyte Corporation and yros Pharmaceuticals Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms - Marketscreener.com
SYRSW (Syros Pharmaceuticals) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023) - Yahoo Finance
Syros Pharmaceuticals (NASDAQ:SYRS) Issues Quarterly Earnings Results - MarketBeat
Earnings call: Syros Pharmaceuticals outlines tamibarotene progress By Investing.com - Investing.com South Africa
Earnings call: Syros Pharmaceuticals outlines tamibarotene progress - Investing.com India
Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ... - Yahoo Finance
Syros Pharmaceuticals Inc (SYRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Syros Pharmaceuticals Inc 주식 (SYRS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Roth David | Chief Medical Officer |
Nov 18 '24 |
Sale |
0.20 |
12,099 |
2,382 |
0 |
| Quirk Gerald E | Chief Legal & Compliance Offic |
Nov 19 '24 |
Sale |
0.22 |
46,657 |
10,321 |
0 |
| Chee Conley | President & CEO |
Nov 18 '24 |
Sale |
0.20 |
134,797 |
26,932 |
0 |
| Haas Jason | Chief Financial Officer |
Nov 18 '24 |
Sale |
0.21 |
137,803 |
28,980 |
0 |
1.80%
0.42%
자본화:
|
볼륨(24시간):